A Validation of the 2018 Revision of International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis: A Cohort Study from China.


Journal

American journal of nephrology
ISSN: 1421-9670
Titre abrégé: Am J Nephrol
Pays: Switzerland
ID NLM: 8109361

Informations de publication

Date de publication:
2020
Historique:
received: 07 01 2020
accepted: 13 03 2020
pubmed: 23 4 2020
medline: 20 7 2021
entrez: 23 4 2020
Statut: ppublish

Résumé

A revision of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification for lupus nephritis has been published in 2018. The current study aimed to verify the utility of this system. A total of 101 lupus nephritis patients from a large Chinese cohort who underwent renal biopsy in Peking University First Hospital were reevaluated by 2 renal pathologists, who had no knowledge of the clinical findings. The association between clinical data at the time of initial renal biopsy and follow-up and pathological features were further analyzed on all patients selected. The mean age of the cohort was 33 years with a male/female ratio of 1:9, and a median follow-up period of 128 months. The presence and extent of mesangial hypercellularity, endocapillary hypercellularity, global and segmental glomerulosclerosis, neutrophil exudation/karyorrhexis, glomerular hyaline deposits, extracapillary proliferation (crescents), tubular atrophy/interstitial fibrosis, and interstitial inflammation were significantly correlated with several clinical renal injury indices (systemic lupus erythematosus disease activity index, serum creatinine value, proteinuria, and C3 level) at the time of biopsy. By multivariable Cox hazard analysis, fibrous crescents, tubular atrophy/interstitial fibrosis, and the modified National Institutes of Health chronicity index were independent risk factors for patients' composite renal outcomes (hazard ratio [HR] 4.100 [95% CI 1.544-10.890], p = 0.005; HR 8.584 [95% CI 2.509-29.367], p = 0.001; and HR 3.218 [95% CI 1.138-9.099], p = 0.028; respectively). The 2018 revision of the ISN/RPS classification for lupus nephritis has utility for prediction of clinical renal outcomes.

Sections du résumé

BACKGROUND
A revision of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification for lupus nephritis has been published in 2018. The current study aimed to verify the utility of this system.
MATERIALS AND METHODS
A total of 101 lupus nephritis patients from a large Chinese cohort who underwent renal biopsy in Peking University First Hospital were reevaluated by 2 renal pathologists, who had no knowledge of the clinical findings. The association between clinical data at the time of initial renal biopsy and follow-up and pathological features were further analyzed on all patients selected.
RESULTS
The mean age of the cohort was 33 years with a male/female ratio of 1:9, and a median follow-up period of 128 months. The presence and extent of mesangial hypercellularity, endocapillary hypercellularity, global and segmental glomerulosclerosis, neutrophil exudation/karyorrhexis, glomerular hyaline deposits, extracapillary proliferation (crescents), tubular atrophy/interstitial fibrosis, and interstitial inflammation were significantly correlated with several clinical renal injury indices (systemic lupus erythematosus disease activity index, serum creatinine value, proteinuria, and C3 level) at the time of biopsy. By multivariable Cox hazard analysis, fibrous crescents, tubular atrophy/interstitial fibrosis, and the modified National Institutes of Health chronicity index were independent risk factors for patients' composite renal outcomes (hazard ratio [HR] 4.100 [95% CI 1.544-10.890], p = 0.005; HR 8.584 [95% CI 2.509-29.367], p = 0.001; and HR 3.218 [95% CI 1.138-9.099], p = 0.028; respectively).
CONCLUSIONS
The 2018 revision of the ISN/RPS classification for lupus nephritis has utility for prediction of clinical renal outcomes.

Identifiants

pubmed: 32320985
pii: 000507213
doi: 10.1159/000507213
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

483-492

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Juan Tao (J)

Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.

Hui Wang (H)

Laboratory of Electron Microscopy, Peking University First Hospital, Beijing, China.

Xiao-Juan Yu (XJ)

Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.

Ying Tan (Y)

Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.

Feng Yu (F)

Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China, yufengevert1@sina.com.
Institute of Nephrology, Peking University, Beijing, China, yufengevert1@sina.com.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China, yufengevert1@sina.com.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China, yufengevert1@sina.com.
Department of Nephrology, Peking University International Hospital, Beijing, China, yufengevert1@sina.com.

Su-Xia Wang (SX)

Laboratory of Electron Microscopy, Peking University First Hospital, Beijing, China.

Mark Haas (M)

Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA.

Richard J Glassock (RJ)

Department of Medicine, David Geffen School of Medicine at UCLA, Laguna Niguel, California, USA.

Ming-Hui Zhao (MH)

Division of Renal, Department of Medicine, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.
Peking-Tsinghua Center for Life Sciences, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH